CTi Biopharma — Cell Therapeutics — Investor Presentation (November 2009)
19 slides from CTi Biopharma's investor presentation, Nov 16, 2009
Slide 1: Corporate Presentation, November 2009
Corporate Presentation November, 2009 James A. Bianco, M.D. Chief Executive Officer Exhibit 99.1
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this presentation include statements about future financial and oper
Slide 3: Overview
Overview Focused on Profitability Pixantrone: a potential breakthrough therapy for lymphoma Potential to become the anthracycline of choice More than 300,000 patients/yr treated with anthracyclines NDA review proceeding on accelerated timetable Only randomized trial to use Complete Remission as endp
Slide 4: A Powerful Cancer Drug Portfolio
A Powerful Cancer Drug Portfolio 3rd line relapse aggressive NHL 1st line Ovarian cancer 1st line aggressive NHL (Randomized Phase 2) 1st line Esophageal cancer +XRT Preclinical Phase I Phase II Phase III Marketed NDA review PH 2-3 completed Phase 3 Phase 2-3 Brostallicin Bisplatinates NP sales = na
Slide 5: Opportunity Assessment
Opportunity Assessment Anthracyclines – 3 rd most commonly used class cytotoxics >300,000 pts receive anthracyclines each year Most effective class of anti-cancer drugs: Curative in lymphoma, leukemia and breast cancer 66,000 US patients/yr diagnosed with NHL 31,600 patients with aggressive NHL will
Slide 6: PIX301 Phase III Study Design
- Randomized Controlled International Multicenter Phase III trial - Relapsed or refractory aggressive NHL (failed 1 st ,2 nd line or beyond) - 140 patients Primary Endpoint* - Complete Remission (CR/CRu) Secondary Endpoints* - Overall Response Rate (ORR) - Responses > 4months - Time to response - Pr
Slide 7: Summary PIX301 Phase III Results
*All response and progression data determined by blinded Independent Assessment Panel (IAP) Superior efficacy over standard of care Superior Complete Remission rates 20% Vs. 5.7% p=0.021 Superior ORR 37% Vs. 14.3% p=0.003 Superior PFS 4.7 months Vs. 2.6 months p=0.007 Superior duration of response >
Slide 8: Commercial Opportunity
8 Commercial Opportunity
Slide 9: Business Issue 1: What is the opportunity for Pixuvri
Business Issue 1: What is the opportunity for Pixuvri in the aggressive Non-Hodgkin’s Lymphoma marketplace?
Slide 10: Physician Data
Physician Data 65% of physicians are either extremely or very likely to prescribe Pixuvri. This indicates a sizable opportunity in the aggressive Non-Hodgkins Lymphoma marketplace. Likelihood of Prescribing Pixuvri QC1b
Slide 11: Physician Data
Physician Data Line Therapy Share of Relapsed Non-Hodgkin Lymphoma Patients Receiving Treatment After Pixuvri Line Therapy Mean % Among Total Physicians\with 1 Or more Third Line Treatment Options (n=76) No statistically significant difference @ 90% confidence level between subgroups Note: Reallocat
Slide 12: Commercial Analysis Assumptions
Commercial Analysis Assumptions Pricing $24/mg – $1,200 vial, = average use 36 vials/patient Exclusivity in the market to 2018 (US) / 2020(EU) Regulatory approval – aggressive relapsed NHL US early Q2-2010, EU Q4 -2010 Modeling assumptions (US only) Only NHL is included 1 line 30,029 patients 2 line
Slide 13: Novartis – CTI Agreement(s)
Novartis – CTI Agreement(s) NVS has option to negotiate a license to pixantrone Provides $104 million in registration/sales milestones $17.5mm on approval for r/r aNHL 28% to 32% royalty on net sales NVS assumes costs and pays CTI to field 35 sales people CTI not obligated to license pixantrone to N
Slide 14: Opaxio
(POPAXIO’ Wcti.
Slide 15: Bioengineered version of Taxol (paclitaxel)
A bioengineered version of Taxol®(paclitaxel) Singer et al. In: Adv Exp Med Biol . 2003; 519:81-99
Slide 16: Opaxio Regulatory Status
Opaxio Regulatory Status Pivotal trial (GOG212) • GOG to conduct an interim “futility” PFS analysis in 1H 2010 • Market size 15,000 to 20,000 patients/year Additional registration trial in lower esophageal cancer • XRT sensitization • Impressive rates of (45%) pathologic complete remission rates wit
Slide 17: Novartis–CTI Agreement(s)
Novartis–CTI Agreement(s) Worldwide license to OPAXIO • Reimburses for 50% of certain expenses • $270M in potential registration and sales milestones • CTI to field 35 FTE at NVS expense up to $9M • NVS to assume development and commercial expenses • Royalties 20%-25% on WW net sales
Slide 18: Capital Structure/Financials
Capital Structure/Financials Dual Listed NASDAQ:CTIC, MTA:CTIC.MI • Liquid stock ~50mm shares/day US/EU (3 month average ) • 580mm shares outstanding Cleaning up Balance Sheet • Redeemed $57.4mm debt • Only common stock outstanding Cash end Q3- $55 million
Slide 19: Upcoming Events
Upcoming Events Upcoming Events Potential GOG futility PFS analysis on st line maintenance trial Key publications for pixantrone PIX 301 follow-up data at American Society of Hematology (ASH) Annual Meeting Investor/Analyst meeting at ASH on Dec. 5 Dr. John Leonard, Weill/Cornell Med College, NY Pre
Cell Therapeutics — Investor Presentation (November 2009) on 6ix